Metabolic hepatotropic regimens in programs of accompanying nutritional support for cancer patients with colorectal cancer and pancreatic cancer: Remaxol in structure of infusion and nutritional therapy

Infusion-nutrient accompanying therapy provides prevention of metabolic complications and their nutrient correction in oncopatients with colorectal cancer (CRС) and pancreatic cancer. Material and methods.  In patients with CRС and pancreatic cancer the effectiveness of detoxification alimentation was evaluated. Nutritional deficiency was specified by alimental-volemic diagnoses (AVD), nutritional risk-by NRI, sarcopenia by bioimedansometry. Hematological indices of intoxication (Krebs index, leukocyte index of intoxication) were calculated according to known formulas. Hepatological parameters (total protein, albumin, bilirubin, ALT, etc.) and the content of blood urea and creatinine, electrolytes were determined by conventional methods, the participation of the intestine in detoxification was monitored by plasma citrulline levels and activity of the intestinal microbiota. The severity of the condition was assessed by APACHE II, the quality of life by ECOG. Results. The relationship between indicators of homeostasis and endotoxicosis, as well as more positive dynamics in the application of detoxification regimens with the addition of Remaxol. Conclusion. In CRC T3–T4, it is advisable to use a combination of nutrient compositions with the addition of hepatotropic pharmaconutrients, in particular, Remaxol.